Strs Ohio Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

Strs Ohio acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 25,100 shares of the company’s stock, valued at approximately $868,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Farther Finance Advisors LLC raised its stake in IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after purchasing an additional 580 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in IDEAYA Biosciences in the 3rd quarter valued at about $38,000. Abich Financial Wealth Management LLC acquired a new position in shares of IDEAYA Biosciences in the 3rd quarter valued at approximately $58,000. Daiwa Securities Group Inc. raised its position in shares of IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after buying an additional 436 shares in the last quarter. Finally, Comerica Bank raised its position in shares of IDEAYA Biosciences by 36.5% in the 4th quarter. Comerica Bank now owns 2,514 shares of the company’s stock valued at $87,000 after buying an additional 672 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Insider Transactions at IDEAYA Biosciences

In related news, Director Jeffrey Stein acquired 50,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was acquired at an average cost of $32.96 per share, for a total transaction of $1,648,000.00. Following the transaction, the director directly owned 54,281 shares in the company, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.50% of the stock is currently owned by corporate insiders.

IDEAYA Biosciences Price Performance

IDYA stock opened at $28.24 on Friday. The company has a 50 day simple moving average of $32.00 and a 200 day simple moving average of $32.96. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -17.65 and a beta of -0.04. IDEAYA Biosciences, Inc. has a 1 year low of $16.84 and a 1 year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. IDEAYA Biosciences’s quarterly revenue was down 39.4% compared to the same quarter last year. During the same period last year, the company posted ($0.82) EPS. On average, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -4.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on IDYA shares. Wells Fargo & Company boosted their target price on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. Guggenheim boosted their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Mizuho dropped their target price on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday. Royal Bank Of Canada boosted their target price on shares of IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Finally, Citigroup boosted their target price on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Fifteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.69.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.